BioCentury
ARTICLE | Clinical News

AN2718: Phase I data

March 9, 2009 7:00 AM UTC

In a Phase I trial in healthy volunteers, AN2718 gel at concentrations of 1.5%, 2.5%, 5.0% and 7.5% and AN2718 cream at concentrations of 0.3% and 1.0% were well tolerated, with irritation rates simil...